Perrier Alexandre, Hainaut Pierre, Lamy Pierre-Jean, Guenoun Alexandre, Nguyen Dinh-Phong, Guerber Fabrice, Troalen Frédéric, Denis Jérôme Alexandre, Boissan Mathieu
Sorbonne Université, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Département de Génétique, 75013 Paris, France.
Université Grenoble-Alpes, CHU de Grenoble-Alpes, Institut pour l'Avancée des Biosciences, Inserm 1209 CNRS UMR 5309, 38700 La Tronche, France.
Bull Cancer. 2022 Feb;109(2):151-169. doi: 10.1016/j.bulcan.2021.11.010. Epub 2022 Jan 7.
In oncology, the identification of targets that correlate with a type of cancer has led to a profound change in the notion of "tumor markers". Technological advances, in particular the development of high-throughput sequencing, have led to the emergence of a new generation of molecular biomarkers for tumors. Despite their limited utility for screening and diagnosis, conventional tumor markers remain interesting for evaluation of prognoses, the choice and optimization of treatments, as well as for monitoring the effectiveness of those treatments. In this article, we revisit the conventional serum markers that are enjoying a 'come back' thanks to the development of high-performance scores based on biological, cytological, clinical, or radiological criteria.
在肿瘤学领域，与某种癌症相关的靶点的识别给“肿瘤标志物”的概念带来了深刻变革。技术进步，尤其是高通量测序技术的发展，催生了新一代肿瘤分子生物标志物。尽管传统肿瘤标志物在筛查和诊断方面的效用有限，但在评估预后、选择和优化治疗方案以及监测治疗效果方面，它们仍然具有重要意义。在本文中，我们重新审视那些因基于生物学、细胞学、临床或放射学标准开发的高性能评分系统而得以“回归”的传统血清标志物。
